Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abagovomab Maintenance Therapy in Epithelial Ovarian Cancer After Complete Response to First-line Chemotherapy
2006-002801-30Phase 2Completed
- Sponsor
- Menarini Group
- Start
- Oct 2006
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epithelial ovarian cancer (EOC) comparing Abagovomab maintenance with Placebo maintenance (2 arms). Primary endpoint: Recurrence-free survival. Started Oct 2006; status: completed.
02
Drugs
abagovomab
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2006-002801-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002801-30.